Adult Dosing
Mild-moderate community-acquired pneumonia
Pediatric Dosing
- Safety and effectiveness in pediatric patients has not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- <30 mL/min: 600 mg/day
- <30 and hepatic impairment: 400 mg/day
- Hemodialysis: Give dose after dialysis
Hepatic Dose Adjustment
- Hepatic impairment: No dose adjustment; contraindicated if history of telithromycin or macrolide-associated hepatic impairment
- Contraindicated in patients with myasthenia gravis. Fatal and life-threatening respiratory failure may occur in patients with myasthenia gravis associated with the use [US Black Box Warning]
- Acute hepatic failure and severe liver injury (fatal) may occur in patients treated with telithromycin
- Telithromycin has the potential to prolong the QTc interval. Therapy should be avoided in patients with congenital prolongation of the QTc interval, and in patients with ongoing proarrhythmic conditions. Cases of torsades de pointes have been reported post-marketing with therapy
- Visual disturbances particularly in slowing the ability to accommodate and the ability to release accommodation may occur with the use of therapy
- Events of transient loss of consciousness including some cases associated with vagal syndrome have also been reported. Therefore avoid tasks such as driving a motor vehicle, operating heavy machinery or engaging in other hazardous activities during treatment
- Serious adverse reactions have been reported in patients taking CYP 3A4 substrates concomitantly
- Clostridium difficile associated diarrhea may occur during therapy
- Prescribing therapy in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria
- Reduce dosage in patients with severe renal impairment
Cautions: Use cautiously in
Pregnancy Category:C
Breastfeeding: Safety unknown. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing mother.
Pricing data from www.DrugStore.com in U.S.A.
- Ketek 400 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
60 mg = $644.99
180 mg = $1896.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Ketek 300 MG Oral Tablet
Ingredient(s): Telithromycin
Imprint: 38AV
Color(s): Orange
Shape: Oval
Size (mm): 14.00
Score: 1
Inactive Ingredient(s): croscarmellose sodium / hypromellose / magnesium stearate / cellulose, microcrystalline / polyethylene glycol / povidone / ferric oxide red / talc / titanium dioxide / ferric oxide yellow
Drug Label Author:
sanofi-aventis U.S. LLC
DEA Schedule:
Non-Scheduled
Drug Name: Ketek 400 MG Oral Tablet
Pill Image:
[
See full size image]
Ingredient(s): Telithromycin
Imprint: H3647;400
Color(s): Orange
Shape: Oval
Size (mm): 13.00
Score: 1
Inactive Ingredient(s): croscarmellose sodium / hypromellose / magnesium stearate / cellulose, microcrystalline / polyethylene glycol / povidone / ferric oxide red / talc / titanium dioxide / ferric oxide yellow
Drug Label Author:
sanofi-aventis U.S. LLC
DEA Schedule:
Non-Scheduled